Zhengye Biotechnology Holding (ZYBT) Liabilities and Shareholders Equity (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $61.5 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $61.5 million, down 10.38% year-over-year; the trailing twelve-month figure through Dec 2025 was $269.4 million (changed N/A YoY), and the FY2025 annual result was $60.7 million, down 10.12% from the prior year.
• Liabilities and Shareholders Equity retreated to $61.5 million in Q4 2025 per ZYBT's latest filing, from $69.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $69.8 million in Q2 2025 and troughed at $61.5 million in Q4 2025.
• A 3-year average of $67.4 million and a median of $69.0 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity declined 1.1% in 2024, then dropped 10.38% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $69.4 million in 2023, then decreased by 1.1% to $68.7 million in 2024, then declined by 10.38% to $61.5 million in 2025.
• Business Quant data shows ZYBT's Liabilities and Shareholders Equity at $61.5 million in Q4 2025, $69.8 million in Q2 2025, and $68.7 million in Q4 2024.